Key result
Aspirin therapy adherence is suboptimal, ranging from 72% to 92%, requiring a multidimensional approach involving patient education and medication innovations to improve compliance.
Aspirin adherence for cardioprotection is suboptimal (72-92%), highlighting the need for multidimensional approaches including patient education and medication innovations to improve adherence.
Requires heightened clinical attention to compliance monitoring; leaves open optimal multidimensional strategies for prospective trials.
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in North America. Aspirin therapy has proven clinical effectiveness in the prevention and treatment of CVD and is one of the most widely used drugs nationwide. However, despite the medication's popularity and utility, adherence to a proper aspirin regimen is suboptimal, resulting in adverse health outcomes and increased health care costs. Our review outlines current knowledge on aspirin therapy adherence, causes of nonadherence, and strategies available to increase adherence to aspirin and medications in general. We demonstrate that, indeed, aspirin adherence rates are suboptimal, ranging from 72% to 92%, and that a combination of patient- and medication-related factors contribute to nonadherence. A multidimensional approach involving patient education and medication innovations to reduce aspirin side effects is imperative to improving rates of aspirin therapy adherence.
No takes yet. Share an insight, caveat, or question.
Duffy et al. (2014) conducted a review in Cardiovascular disease. Aspirin therapy was evaluated on Aspirin adherence rates. Aspirin therapy adherence is suboptimal, ranging from 72% to 92%, requiring a multidimensional approach involving patient education and medication innovations to improve compliance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: